PPL-100

DB05961InvestigationalSmall molecule

Investigated for use/treatment in HIV infection.

Mechanism: PPL-100 is a promising protease inhibitor which binds specifically to HIV-1 protease. It has been shown activity against several HIV-1 strains specifically selected for key mutations that render these strains resistant to currently marketed protease inhibitors
Curator reviewed
Primary indication: Investigated for use/treatment in HIV infection.Curator reviewed
Formula / weight: C₃₃H₄₄N₄O₆S · 624.791 g/mol (avg)
Code names: MK-8122 · MX-100 · PL 100 (PHARMACEUTICAL) · PPL 100 · TMB-607

Resolves to

Compound

Structure

InChIKeyQAHLFXYLXBBCPS-IZEXYCQBSA-NSMILESCOC(=O)N[C@@H](C(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)NCCCC[C@@H](CO)N(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1

Targets

What you can answer from here — as of January 29, 2025

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with PPL-100, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.